TDP-43

National Institute on AgingUS$10.8mNational Institute of Neurological Disorders and StrokeUS$3.3m

• Defining short RNA therapeutics that combat TDP-43 proteinopathy connected to AD and ADRDs.

  National Institute on AgingUniversity of PennsylvaniaUS$3.4m2025–2029

• Disease Mechanism and Therapy in TDP-43 Proteinopathies and Dementias

  National Institute of Neurological Disorders and StrokeUniversity of California, San DiegoUS$760.1k1989–2027

• Discovery and Trial Ready Cohort for Limbic Predominant Age Related TDP-43 Encephalopathy (TRC LATE)

  National Institute on AgingUniversity of California-irvineUS$3.1m2025–2030

• Diagnosis and Risk factors of hippocampal sclerosis of aging and limbic predominant age related TDP-43 encephalopathy; common Alzheimer’s mimics

  National Institute on AgingUniversity of California-irvineUS$1.7m2019–2029

• The impact of progranulin species on TDP-43 proteolysis and pathobiology

  National Institute of Neurological Disorders and StrokeUniversity of California, San FranciscoUS$1.3m2025–2027

• Molecular and cellular underpinnings of limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC)

  National Institute on AgingBrigham and Women's HospitalUS$1.3m2023–2028

• Biophysical and Pathophysiological Studies of TDP-43/Tau Interaction

  National Institute of Neurological Disorders and StrokeUniversity of FloridaUS$547.3k2024–2029

• Biochemical and molecular heterogeneity of human TDP-43 proteinopathies in age-related dementias

  National Institute on AgingUniversity of PennsylvaniaUS$510.8k2022–2027

• Environmental risk factors linked to TDP-43 proteinopathies

  National Institute on AgingUniv of North Carolina Chapel HillUS$734.6k2024–2029

• TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation

  National Institute of Neurological Disorders and StrokeUniversity of California, San DiegoUS$749.9k2021–2026